In vitro data support a role for the a6b4 integrin in tumor cell migration and invasion, particularly in breast carcinoma cells, but clinical data on this potentially important integrin are limited. The b4 integrin subunit has been shown to cluster with genes characteristic of basal/myoepithelial cells in cDNA microarray analyses of breast cancer, and the subset of breast cancers with increased expression of genes characteristic of basal/ myoepithelial cells appears to be particularly aggressive. The purpose of this study was to determine whether a6b4 integrin expression correlates with aggressive clinicopathologic features of breast cancer and whether expression of this integrin has prognostic significance in early breast cancer. We evaluated tumor expression of the b4 integrin subunit gene in a cohort of patients with early invasive breast carcinoma by in situ hybridization and correlated expression levels with multiple clinicopathologic characteristics. We also evaluated expression of laminin-5 protein, the principal ligand of a6b4, in this patient cohort. Although we observed a slight trend towards decreased disease-free survival for patients whose tumors had high b4 gene expression and coexpression of laminin-5, this did not reach statistical significance (P ¼ 0.11). However, we did observe a correlation between b4 mRNA expression and both tumor size (P ¼ 0.01) and tumor nuclear grade (Po0.01). These results do not demonstrate prognostic significance for b4 gene expression and/or laminin-5 protein expression in early breast cancer, but increased b4 gene expression in larger tumors and in higher grade tumors does support a potential role for the a6b4 integrin in tumor progression.
A great deal of effort has gone into identifying markers for invasive breast carcinoma that can predict response to particular therapies. Hierarchical clustering analysis performed on cDNA microarray data has revealed a few distinct subgroups of invasive breast carcinomas that can be classified according to their patterns of gene expression. 1 One such subgroup has been referred to as the basal/ myoepithelial group. A variety of genes expressed in basal cells and myoepithelial cells have been noted to cluster in a distinct subset of tumors comprising between 15 and 37% of invasive breast carcinomas. [1] [2] [3] [4] [5] Clinically, this appears to be an aggressive group of tumors. Two other groups whose gene expression patterns cluster as distinct subtypes include an estrogen receptor (ER)-positive group and a HER-2/neu-positive group. Both ER-positive and HER-2/neu-positive tumors currently have targeted therapies available, but the basal/myoepithelial group does not. Among the gene products characteristic of the basal/myoepithelial group is the b4 integrin subunit. 1 Integrins are protein heterodimers that function as the major cell surface receptors for extracellular matrix proteins in multicellular animals. 6, 7 Each integrin heterodimer is composed of a single a and a single b subunit. At present, 18 a subunits and eight b subunits have been identified, which combine to form 24 different integrins. 6 The b4 subunit is interesting because, in contrast to other integrin subunits that contain small cytoplasmic domains of around 50 amino acids, the large b4 cytoplasmic domain contains approximately 1000 amino acids (in most of its splice variants) and has signaling functions distinct from those of other integrins. [8] [9] [10] [11] [12] [13] [14] The b4 subunit is expressed only in combination with a6, so detection of the b4 subunit indicates expression of the a6b4 integrin. 6 This integrin mediates signal transduction through pathways known to be important in tumor cell motility and invasion. The a6b4 integrin or its downstream signaling effectors, therefore, could be important therapeutic targets for a subgroup of breast carcinomas lacking targeted therapies.
The a6b4 integrin functions as a receptor for laminin-5, a component of epithelial cell basement membranes. [15] [16] [17] [18] [19] [20] [21] A previous retrospective study by Tagliabue et al 22 using frozen tumor specimens from 80 patients with invasive breast carcinoma found an association between a6b4 integrin expression and poor clinical outcome. Tumors expressing both a6b4 and laminin were reported to have a particularly poor prognosis, but expression of the laminin-5 isoform was not specifically evaluated. 22 A few primary breast carcinomas have been reported to coexpress a6b4 and laminin-5, 23 but reported data are too limited to know the extent to which a6b4 and laminin-5 are coexpressed in invasive breast carcinoma. Coexpression of a6b4 and laminin-5 does not appear to be necessary for the function of a6b4, as some in vitro data suggest that a6b4 has important signaling functions that are ligand independent. 16 Immunohistochemical staining for integrins can be successfully performed on frozen tissue sections, but we have had inconsistent staining results on formalin-fixed, paraffin-embedded tissues using multiple antibodies to the b4 integrin subunit. We recently reported that an oligonucleotide probe for the b4 integrin subunit is highly sensitive in detecting b4 mRNA in formalin-fixed, paraffinembedded tissues. 24 In this study, we evaluated tumor expression of b4 mRNA and laminin-5 protein retrospectively in a cohort of patients with early invasive breast carcinoma who received no adjuvant chemotherapy or tamoxifen. Our purpose was to determine whether expression of a6b4 integrin or its principal ligand correlates with aggressive clinicopathologic features of breast cancer and whether their expression has prognostic significance in early breast cancer.
Materials and methods
This study was approved by the MD Anderson Institutional Review Board as Protocol LAB02-426. Tissue specimens from patients with lymph nodenegative invasive breast carcinoma who had surgery performed at MD Anderson Cancer Center (MDACC) between July of 1978 and October of 1995 were included in the study if the patients received no adjuvant tamoxifen or chemotherapy and if archival tissue blocks and clinical follow-up information were available. Clinical data were obtained from a database in the MDACC Department of Breast Medical Oncology. Formalin-fixed, paraffin-embedded tissue blocks were identified in the MDACC surgical pathology archives for 230 patients meeting study criteria.
To detect b4 integrin subunit mRNA, we used a custom oligonucleotide probe (Research Genetics, Huntsville, AL, USA) that we previously reported to be highly sensitive and specific for the b4 integrin subunit in archival paraffin tissue sections. 24 The probe was designed with a 3 0 -hyperbiotinylated tail and the following sequence: 5 0 -GTAGTCCCTGGGCA GTGTGGTCGAG-TGTGAGTGTTCTGAG-3 0 . The GC content of the probe was 56%. The probe was designed to recognize a 40-nucleotide sequence in the connecting segment of the b4 cytoplasmic domain between two pairs of fibronectin type III repeats in a region that does not overlap with the insertions for variants b4B and b4C [8] [9] [10] [11] [12] [13] [14] ( Figure 1 ). Paraffin sections were cut at 4-mm intervals using RNase-free conditions. All instruments, glassware, and slides were washed overnight in 0.1% DEPC water, and histologic sections were cut using a 0.1% DEPC waterbath. The tissue sections were mounted on silane-treated ProbeOn slides (Fisher Scientific, Pittsburgh, PA, USA) and preheated at 651 for 45 min before beginning the assay.
In situ hybridization was performed using the Microprobe System (Fischer Scientific, Pittsburgh, PA, USA) and the chromogen Fast Red (Biomeda Corp., Foster City, CA, USA) as previously described. 25, 26 Briefly, the glass slides were placed into the Microprobe holder and dewaxed with autodewaxer and dehydrated using Autoalcohol (Research Genetics). This was followed by digestion with Pepsin Reagent (Fisher Scientific) for 4 min at 1001C. Sections were hybridized with the probe at 451C for 1 h, then washed 3 times at 451C with 0.3 M NaCl and 0.03 M sodium citrate. Incubation with chromogen was performed at 451C for 30 min, followed by an additional incubation for 10 min. Phosphatase Enhancer Reagent (Fisher Scientific) was applied to the samples for 1 min prior to both chromogen incubations. In situ hybridization with a polyd(T) 20-oligonucleotide probe (Research Genetics) was also performed on each case to verify the integrity of mRNA, and tumor samples with an Figure 1 Schematic diagram of the b4 integrin subunit. The oligonucleotide probe used for in situ hybridization recognizes a 40-nucleotide sequence in the connecting segment between the two pairs of fibronectin type III repeats in a region that does not overlap with the insertions for variants b4B and b4C. b4 integrin in breast cancer LK Diaz et al absence of polyd(T) staining were excluded from analysis.
Immunohistochemical staining for laminin-5 was performed using a monoclonal antibody to the laminin-5 g2 chain (clone D4B5, Chemicon) following Protease XXIV tissue pretreatment and a standard immunoperoxidase assay with diaminobenzidine (DAB) chromogen. Immunohistochemical staining for ER, progesterone receptor, and HER-2/ neu was performed with monoclonal antibodies 6F11 (Novocastra), 1A6 (Neomarkers), and e2-4001 (Neomarkers), respectively.
In situ hybridization for b4 mRNA was scored as follows: negative, no cytoplasmic signal; low, weak cytoplasmic signal in at least 5% of cells; and high, strong cytoplasmic signal in at least 5% of cells. Immunohistochemical staining for laminin-5 was regarded as positive if at least 5% of cells had cytoplasmic staining or if staining was observed immediately surrounding invasive tumor cells (peritumoral staining). Peritumoral staining was scored as follows: negative, less than 5% staining; low, greater than or equal to 5% but less than 20% staining; and high, greater than or equal to 20% staining. Staining for HER-2/neu was interpreted as positive for overexpression if at least 10% of tumor cells had complete membranous staining, and tumors with at least 10% nuclear staining were interpreted as positive for ER and progesterone receptor.
The Cochran-Armitage trend test was used to test for trends in binomial proportions across levels of a single factor or covariate. The Kruskal-Wallis rank sum test was used to compare groups of independent continuous variables. Disease-free survival (DFS) was defined as the interval from the date of surgery to the date of disease recurrence or death from breast cancer or to the last follow-up date. Disease-related survival (DRS) was defined as the interval from the date of surgery to the date of death from breast cancer or to the last follow-up date. Patients who died from causes other than breast cancer were censored when DRS was considered. Survival was estimated by using the Kaplan-Meier product limit method. The two-sided log-rank test was used to test the association between particular factors and survival. Statistical analyses were carried out using SAS 8.02 (SAS, Cary, NC, USA) and S-plus version 6 (Insightful Corp., Seattle, WA, USA).
Results
The median patient age for the 230 patients included in the study was 58 years (range: 28-83 years). A total of 82% of patients were white, 8% were Hispanic, 7% were black, and 3% were Asian. In all, 81% were postmenopausal. The surgical procedure for 25% of patients was lumpectomy with axillary dissection, and 75% had a modified radical mastectomy. In all, 41% of patients received adjuvant radiation therapy, none received adjuvant tamoxifen, and none received chemotherapy. There were 139 T1, 88 T2, and 3 T3 tumors. The median tumor size was 2.0 cm (range: 0.6-7.0 cm). Histologic subtypes included 91% invasive ductal carcinomas, 6% invasive lobular carcinomas, and 3% other types. A total of 71% of tumors were ER positive, and 32% had HER-2/neu overexpression. The median clinical follow-up was 15 years.
During the 15-year follow-up period, there was disease recurrence in 63 patients. A total of 90 patients died, and 39 deaths were attributed to breast cancer. The estimated DFS (survival without tumor recurrence) for the entire group at 5 and 10 years was 80 and 74%, respectively. The estimated DRS (noncancer-related deaths censored) at 5 and 10 years was 94 and 86%, respectively. Standard pathologic features associated with DFS were tumor size (P ¼ 0.04) and the presence of lymphovascular invasion (P ¼ 0.03, Table 1 ). The only standard pathologic feature found to be associated with DRS was tumor size (P ¼ 0.04, Table 2 ).
A total of 200 tumors were technically satisfactory for evaluation of b4 mRNA expression by in situ hybridization. Two of these had an absence of polydT staining and were excluded from the analysis. For the remaining 198 cases, a high level of the b4 integrin subunit mRNA was observed in 50 cases (25%) (Figure 2) . No association was found between b4 mRNA expression and patient age, hormone receptor positivity, HER-2/neu overexpression, or lymphovascular invasion. There was a strong correlation between high b4 mRNA expression and tumor nuclear grade (Po0.01, Table 3 ), and high levels of b4 mRNA were also associated with larger tumor size (P ¼ 0.01, Table 3 ). In all, 5-and 10-year DFS for tumors with negative b4 expression was 84 and 73%, respectively, compared to 79 and 77% for tumors with high b4 mRNA expression (Table 1) . 5-and 10-year DRS for tumors with negative b4 expression was 96 and 89%, respectively, compared to 94 and 85% for tumors with high b4 expression ( Table 2) . None of these survival differences was statistically significant (Figure 3a, b) .
A total of 212 tumors were technically satisfactory for evaluation of laminin-5 immunohistochemical staining. Laminin-5 protein expression was observed in a linear staining pattern surrounding all normal ducts and lobules (Figure 4a ) and around all ducts involved by ductal carcinoma in situ (DCIS) (Figure 4b ). Extracellular deposition of laminin-5 immediately adjacent to invasive tumor cells was observed in 53 cases (24.5%) (Figure 4c, d) . Laminin-5 was identified within the cytoplasm of invasive tumor cells in only 12 cases (5.7%) ( Figure  4e ). Only one case with cytoplasmic staining lacked extracellular deposition of laminin-5. A strong negative association was observed between peritumoral laminin-5 deposition and ER positivity Table 3 ). A negative association was also observed between peritumoral laminin-5 deposition and HER-2/neu overexpression (P ¼ 0.02, Table 3 ). No association was found between peritumoral laminin-5 staining and patient age, tumor size, nuclear grade, progesterone receptor positivity, or lymphovascular invasion. No statistically significant differences in 5-and 10-year disease-specific (Table 1) or disease-related (Table 2) survival were observed for patients whose tumors had laminin-5 protein expression compared to patients whose tumors were negative for laminin-5 (Figure 3c, d) .
A total of 194 tumors were technically satisfactory for evaluation of both b4 mRNA expression by in situ hybridization and laminin-5 expression by immunohistochemical staining. Most tumors with upregulation of b4 gene expression lacked detectable amounts of peritumoral laminin-5 deposition.
No correlation was observed between b4 gene expression and peritumoral laminin-5 deposition ( Table 4) . As shown in Figure 5a , no recurrences were observed for patients whose tumors were negative for b4 gene expression but had high peritumoral laminin-5 deposition, but the number of patients in this group 6 was too small for this finding to have statistical significance. There was a slight trend towards decreased disease-free survival for patients whose tumors had high b4 gene expression and either low or high peritumoral laminin-5 deposition (Figure 5b ), but the number of patients and events in this group (10 patients and five recurrences) were relatively few, and this result is not statistically significant (P ¼ 0.11). There were insufficient disease-related deaths to evaluate DRS for subsets of patients whose tumors had particular combinations of b4 and laminin-5 positivity. 
Discussion
By linking information from the cell's environment to intracellular molecules, integrins are able to regulate processes as diverse as ion channel trafficking, intracellular protein kinase activity, and the organization of the intracellular actin cytoskeleton. 6, 27 Integrin signaling pathways also converge with those mediated by growth factor receptors, providing a mechanism whereby a particular extracellular environment can modulate the growth regulatory properties of cells. 28, 29 Consequently, integrin signaling plays an important role in cell cycle regulation, cell survival, differentiation, and motility. 6 Alterations in integrin signaling are also important in various pathologic conditions. The a6b4 integrin, in particular, appears to be important in the progression of some types of malignancy, including invasive breast carcinoma. [15] [16] [17] [18] [19] [20] [21] 28, 30, 31 In breast carcinoma cell lines, ligation of the a6b4 integrin activates the PI3K-Akt pathway, thereby promoting tumor cell survival. 16 The mTOR pathway downstream of a6b4 leads to increased VEGF production, which not only stimulates angiogenesis but also promotes tumor cell survival through an autocrine loop mechanism. 20 Activation of PI3K by a6b4 also leads to increased tumor cell invasiveness. 15, 16, 19, 28, 31 Tumor cell invasion involves the formation of actin-containing motility structures such as lamellipodia and filopodia, and a6b4 has been shown to localize to these structures in invasive tumor cells. 17, 18 Furthermore, ligation of a6b4 activates the Ras-MAP kinase pathway, 32 and signaling through this pathway may stimulate cell motility through activation of myosin light-chain kinase and phosphorylation of nonmuscle myosin II light chain, the catalytic component of nonmuscle myosin II. 32, 33 Invasive breast carcinomas that overexpress a6b4 may acquire a myoepithelial-like phenotype. Myoepithelial cells are present in the ducts of normal breast tissue, where they are in contact with the basement membrane surrounding the ducts. Myoepithelial cells are known to be proliferative and move through the adjacent stroma in some physiologic conditions. 35 Tumors that overexpress a6b4 may similarly have an increased capacity for stromal invasion. This would be consistent with in vitro data showing increased invasiveness of breast carcinoma cell lines following transfection of a6b4-negative breast carcinoma cells with full-length b4. 16 In cDNA microarray studies of invasive breast carcinoma, the basal/myoepithelial group of tumors is defined as those tumors expressing increased basal/myoepithelial markers compared to a reference set of nonmyoepithelial cell lines. 1 In hierarchical clustering analysis, tumors overexpressing the b4 integrin subunit and those with increased laminin-5 expression have been reported to cluster together. 1 Some invasive tumors have a high DCIS component, which is a noninvasive malignant component still confined to ducts surrounded by benign myoepithelial cells. 36, 37 Tumors that cluster with the basal/myoepithelial group in hierarchical clustering analysis might include tumors with a high DCIS component (tumors that contain many associated benign myoepithelial cells). Such tumors would be expected to show a high correlation between expression of laminin-5 and other basal/ myoepithelial markers because normal myoepithelial cells produce laminin-5. 38 Histologic evaluation of gene expression is necessary to determine whether particular cellular components of a tumor coexpress certain gene products. In our study, only 20% of the invasive tumors with high a6b4 expression had detectable amounts of laminin-5 by immunohistochemistry.
Both subunits of the a6b4 integrin have multiple known splice variants. No clear functional differences between the two a6 cytoplasmic variants have yet been identified when the a6 subunits are in association with b4. [39] [40] [41] [42] There are five known cytoplasmic splice variants of the b4 subunit. [8] [9] [10] [11] 14 Compared to b4A, the most common variant, b4B and b4C contain inserts of 53 and 70 amino acids, respectively. Twenty one base pairs are deleted from b4D. The fifth variant, b4E, has a markedly 43 Some data suggest that these variants, present at a constant ratio in the various tissues and cell lines tested, result from aberrant splicing events that may not have biologic significance. 43 The b4 probe used in this study recognizes each of the variants except b4E, which would not be expected to function in signaling because of its truncated cytoplasmic domain. 14 Our study confirms that a group of invasive breast carcinomas exists that overexpresses an integrin characteristic of myoepithelial cells, and that the group with high levels of this integrin represents approximately 25% of lymph node-negative invasive breast carcinomas. Although cDNA microarray analyses suggest that there is little overlap between the basal/myoepithelial group and the ER-positive and HER-2/neu-positive subsets, we did not observe either a positive or negative correlation between b4 expression and ER positivity or HER-2/neu overexpression. We also found no clear association between expression of b4 mRNA and laminin-5 protein. Although we cannot rule out the possibility that low levels of laminin-5 below the threshold for detection by immunohistochemical staining might still function in ligand-mediated signaling in invasive breast carcinoma, the deposition of laminin-5-rich basement membranes at the leading edge of invasive tumors, as has been reported for colonic adenocarcinomas, 23 does not appear to occur in most of the invasive breast carcinomas we examined.
We found no correlation between a6b4 overexpression and disease-free or disease-specific survival in this patient cohort. These findings do not support a previous study by Tagliabue et al 22 reporting a positive correlation between a6b4 expression in invasive breast carcinoma and decreased survival. Findings from the previous smaller study are surprising considering the small number of patients in the study (80 patients) and the low number of events (seven deaths). In that study, a6b4 protein expression was evaluated by immunohistochemistry using frozen tissue specimens. As a result of the difficulty in accurately detecting a6b4 protein expression in archival paraffin-embedded tissues, we examined b4 mRNA expression by in situ hybridization. We previously reported good sensitivity for detecting b4 mRNA with the probe used in our study, 24 and the proportion of cases with high b4 mRNA expresssion in our study (25%) is within the range of 15-37% reported for basal/myoepithelial tumors by cDNA microarray analyses. 1-5 Therefore, we believe that b4 mRNA detection in our study is reasonably accurate. Some cases with high b4 mRNA expression may not express cell-surface b4 integrin in breast cancer LK Diaz et al protein, however, and this could account for some differences between the two studies. Perhaps more importantly, the study by Tagliabue et al 22 included many lymph node-positive patients. The prognostic significance of a6b4 expression may be different in high-stage patients, as has been reported for HER-2/neu overexpression. 44, 45 We did observe a slight trend towards decreased DFS for patients whose tumors had high b4 gene expression and coexpression of laminin-5, and this would support the previous findings by Tabliabue et al, but our results did not reach statistical significance (P ¼ 0.11). It is possible that a larger clinical study could confirm the adverse prognostic significance of a6b4 integrin and laminin-5 coexpression in early invasive breast carcinoma, so the prognostic significance of a6b4 and laminin-5 coexpression should not be discounted based on our results alone.
Regardless of whether the a6b4 integrin has prognostic significance, the increased expression of b4 mRNA we observed in larger tumors and in higher grade tumors does support the hypothesis that a6b4 may play a role in tumor progression, as suggested by recent in vitro studies. [15] [16] [17] [18] [19] [20] [21] 28, 30, 31 The a6b4 integrin identifies a subset of patients with a basal/myoepithelial phenotype for which targeted therapies have not been identified. As opposed to most other markers of the basal/myoepithelial group, the a6b4 integrin is a cell surface receptor that mediates signal transduction, so it may be an ideal therapeutic target for breast cancer. If therapies are devised which target a6b4 signaling pathways, Figure 5 Kaplan-Meier disease-free survival (DFS) curves for patients with node-negative invasive breast carcinoma in relation to combined tumor b4 mRNA level and peritumoral laminin-5 protein expression level.
detection of the a6b4 integrin could be an important test to identify those patients who might respond to such targeted therapies in the future.
